Premium
EBV‐positive non‐Hodgkin's lymphoma developing after phenytoin therapy
Author(s) -
GarciaSuArez Julio,
DOMINGUEZFRANJO PURIFICACION,
DEL CAMPO J. Francisco,
HERRERO BEGOÑA,
MUÑOZ M. ANGELES,
PIRIS MIGUEL A.,
PARDO ANA
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1905.x
Subject(s) - lymphoma , medicine , serology , phenytoin , cd20 , epstein–barr virus , chop , immunology , nodular sclerosis , antigen , pathology , antibody , virus , epilepsy , hodgkin lymphoma , psychiatry
We report the first case of Epstein Barr virus (EBV) positive non‐Hodgkin's lymphoma occurring 20 years after continuous phenytoin therapy for idiopathic epilepsy. This malignant lymphoproliferative disease was preceded by an phenytoin‐associated benign reactive lymphadenopathy. Serological findings suggested a chronic active EBV infection. Immunohistochemistry showed that neoplastic cells expressed B antigens (CD20, lambda) and the bcl‐2 protein. The presence of EBV‐encoded latent membrane protein 1 (LMP 1) was also expressed on neoplastic cells. Cytotoxic chemotherapy (CHOP) reversed the non‐Hodgkin's lymphoma.